Abstract:Objective To investigate the effects of intensity-modulated radiation therapy （IMRT）combined with concurrent chemotherapy on tumor marker levels，clinical efficacy and quality of life in patients with advanced cervical cancer. Methods A total of 82 patients with advanced cervical cancer who underwent treatment in the First Affiliated Hospital of Anhui University of Science and Technology between January 2020 and December 2024 were selected prospectively. They were divided into two groups using a random number table：the control group（n=41）and the observation group（n=41）. The control group received chemotherapy alone，while the observation group received IMRT in combination with concurrent chemotherapy. The clinical efficacy，2-year survival rate，disease -free survival rate，incidence of adverse reactions，serum tumor markers［squamous cell carcinoma antigen（SCC-Ag），carcinoembryonic antigen（CEA），carbohydrate antigen 125（CA-125）］，and Functional Assessment of Cancer Therapy-General（FACT-G）scale scores were observed and recorded for both groups. Results The clinical efficacy，2-year survival rate，and disease-free survival rate in the observation group（90.24%，92.68%，87.80%，respectively）were significantly higher than those in the control group（73.17%，73.17%，65.85%，respectively）（P<0.05）. The total incidence of adverse reactions in the observation group was significantly lower than that in the control group（7.32% vs 26.83%，χ2=5.513，P<0.05）. After treatment，the levels of SCC-Ag，CEA，and CA-125 in the observation group were significantly lower than those in the control group，while the FACT -G scores were higher（P<0.05）. Conclusion The combination of IMRT and concurrent chemotherapy not only substantially enhances clinical effectiveness，survival rates，and disease -free survival rates but also significantly reduces the concentration of tumor markers，markedly improves patients’’ quality of life，and effectively decreases the incidence of adverse events.